A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema

Bloomquist, Kira; Hayes, Sandi; Adamsen, Lis; Møller, Tom; Christensen, Karl Bang; Ejlertsen, Bent Laursen; Oturai, Peter Sandor

Published in:
B M C Cancer

DOI:
10.1186/s12885-016-2548-y

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Bloomquist, K., Hayes, S., Adamsen, L., Møller, T., Christensen, K. B., Ejlertsen, B., & Oturai, P. (2016). A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol. DOI: 10.1186/s12885-016-2548-y
A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol

Kira Bloomquist1*, Sandi Hayes2, Lis Adamsen1, Tom Møller1, Karl Bach Christensen3, Bent Ejlertsen4 and Peter Oturai5

Abstract

Background: In an effort to reduce the risk of breast cancer-related arm lymphedema, patients are commonly advised to avoid heavy lifting, impacting activities of daily living and resistance exercise prescription. This advice lacks evidence, with no prospective studies investigating arm volume changes after resistance exercise with heavy loads in this population. The purpose of this study is to determine acute changes in arm volume after a session of low- and heavy-load resistance exercise among women undergoing adjuvant chemotherapy for breast cancer at risk for arm lymphedema.

Methods/Design: This is a randomized cross-over trial. Participants: Women receiving adjuvant chemotherapy for breast cancer who have undergone axillary lymph node dissection will be recruited from rehabilitation centers in the Copenhagen area. Intervention: Participants will be randomly assigned to engage in a low- (two sets of 15–20 repetition maximum) and heavy-load (three sets of 5–8 repetition maximum) upper-extremity resistance exercise session with a one week wash-out period between sessions. Outcome: Changes in extracellular fluid (L-Dex score) and arm volume (ml) will be assessed using bioimpedance spectroscopy and dual-energy x-ray absorptiometry, respectively. Symptom severity related to arm lymphedema will be determined using a visual analogue scale (heaviness, swelling, pain, tightness). Measurements will be taken immediately pre- and post-exercise, and 24- and 72-hours post-exercise. Sample size: A sample size of 20 participants was calculated based on changes in L-Dex scores between baseline and 72-hours post exercise sessions.

Discussion: Findings from this study are relevant for exercise prescription guidelines, as well as recommendations regarding participating in activities of daily living for women following surgery for breast cancer and who may be at risk of developing arm lymphedema.

Trial registration: Current Controlled Trials ISRCTN97332727. Registered 12 February 2015.

Keywords: Lymphedema, Breast cancer, Resistance exercise
Background

Approximately 20% of breast cancer survivors develop breast cancer-related arm lymphedema BCRL [1], with an estimated 80% of cases presenting within the first two years of diagnosis [2]. It is associated with significant impairments in gross and fine motor skills affecting work, home and personal care functions, as well as recreational and social relationships [3, 4]. While the etiology of BCRL is unknown [1, 5], findings from a systematic review and meta-analysis from 2013 [1] including 72 studies demonstrate that axillary lymph node dissection, more extensive breast surgery, radiotherapy, chemotherapy, being overweight or obese and physical inactivity are consistently associated with increased BCRL risk [1].

Participation in resistance exercise has been found to be a safe and effective exercise modality among breast cancer survivors at risk of BCRL [6, 7], and is associated with increases in lean muscle mass and strength, which in turn positively affect physical function and ability. Furthermore, findings from a recent meta-analysis [6] suggest that resistance exercise can reduce the risk of BCRL versus control conditions (OR = 0.53 (95% CI 0.31–0.91); I² = 0%). However, the current evidence-base is derived from studies that have evaluated resistance exercise intensities considered to be low to moderately heavy (60–80% of 1 repetition maximum (RM) or 8–15 RM) [6, 7]. Yet, exercise science literature indicates that heavy-load resistance exercise (80–90% 1RM or 5–8 RM) [8] is more effective than low-to moderate-load resistance exercise in generating muscle strength gains [9]. There is therefore a clear need for studies evaluating the safety of heavy-load resistance exercise in the at-risk population [7].

In a novel study by Cormie et al. [10], which evaluated the effect of low- and heavy-load resistance exercise among a sample with BCRL, lymphedema status and lymphedema symptoms remained stable immediately after exercise, and 24- and 72-hours after exercise, irrespective of load. While these findings provide important information for women with BCRL, the purpose of this study is to determine acute changes in extracellular fluid, arm volume and associated lymphedema symptoms after a session of low- and heavy-load resistance exercise in women at risk for BCRL. It is hypothesized that no interlimb differences in extracellular fluid, arm volume or lymphedema-associated symptom severity will be observed over time or between resistance exercise loads.

Design

This study is a randomized, cross-over trial (Table 1 here).

---

**Table 1** Trial registration data

| Primary registry and trial identify number | Current Controlled Trials ISRCTN97332727. |
| Date of registration in primary registry | 12 February 2015. |
| Secondary identifying numbers | H-3-2014-147, 30-1430 |
| Source of monetary or material support | University Hospitals Centre for Health Research, Copenhagen University Hospital Rigshospitalet |
| Primary sponsor | University Hospitals Centre for Health Research, Copenhagen University Hospital Rigshospitalet |
| Secondary sponsor | |
| Contact for public queries | KB, MHS, PhD-stud. kibl30@hotmail.com, (45) 35347362, Blegdamsvej 9 (afsnit 9701), 2100 Copenhagen |
| Contract for scientific queries | KB, MHS, PhD-stud. kibl30@hotmail.com, (45) 35347362, Blegdamsvej 9 (afsnit 9701), 2100 Copenhagen |
| Public title | A trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: Study Protocol |
| Scientific title | A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: Study Protocol |
| Countries of recruitment | Denmark |
| Health condition or problem studied | Breast cancer-related arm lymphedema |
| Intervention | Heavy vs low load resistance exercise for the upper extremities |
| Key inclusion and exclusion criteria | Inclusion criteria: > 18 years of age, unilateral breast cancer, axillary node dissection, undergoing adjuvant chemotherapy for breast cancer |
| Safety | Exclusion criteria: Previously treated for breast cancer, diagnosis of BCRL and/or currently receiving treatment for BCRL, or having conditions hampering resistance exercise of the upper body, or having participated in regular upper-body heavy resistance exercise during the last month |
| Study type | Interventional |
| Date of first enrolment | 31-03-2015 |
| Target sample size | 40 |
| Recruitment status | Recruiting |
| Primary outcome | Arm extracellular fluid (L-dex score) post-, 24- and 72 h post exercise |
| Key secondary outcomes | Arm volume (ml) post-, 24- and 72 h post exercise |
**Methods**

**Participants / Recruitment**

Twenty women allocated to adjuvant chemotherapy for breast cancer consisting of three cycles of 3-weekly epirubicin followed by three cycles of 3-weekly docetaxel will be recruited from municipality lead rehabilitation centers in the Copenhagen area and from a waiting list to the Body and Cancer program [11, 12], at the University Hospitals Center for Health Research (UCSF) at the Copenhagen University Hospital, Rigshospitalet. All patients will be screened for inclusion by health professionals (nurse or physical therapist) at the respective centers. Potential participants fulfilling inclusion criteria; over 18 years of age, unilateral breast surgery, axillary node dissection, and initiating /undergoing adjuvant chemotherapy for breast cancer (stage I - III) will be contacted during their first three cycles of chemotherapy (Fig. 1). Patients previously treated for breast cancer, with a diagnosis of BCRL and/or currently receiving treatment for lymphedema, or having conditions hampering resistance exercise of the upper body, or having participated in regular (>1 × / week) upper-body heavy resistance exercise during the last month will be excluded.

Those fulfilling study criteria and expressing interest in study participation will thereafter be screened for BCRL by the first author after the third cycle of chemotherapy, using bioimpedance spectroscopy (BIS). Furthermore, in accordance with common toxicity criteria (CTC) v3.0 lymphedema criteria for the limb [13], patients will be visually inspected to detect differences in signs of swelling between arms. Those presenting with BCRL, defined as a lymphedema index (L-Dex) score of 10 or greater [14–16] (as assessed by BIS), and/or visual signs of swelling (obscuration of anatomic architecture or pitting edema) of the at-risk arm [13] will be referred for treatment, and will not be included in the study.

Written and oral information regarding the study will be delivered by the first author, as well as obtainment of informed written consent.

**Concealed randomization**

Prior to the study, a computer-generated random sequence will be generated by an external researcher not otherwise affiliated with the study, and concealed in opaque envelopes. Group assignment will be disclosed to the first author by telephone after study inclusion and participation in the familiarization period. Participants will be allocated using a 1:1 ratio to partake in either low- or heavy-load resistance exercise first.

**Exercise sessions**

Participants will engage in a familiarization period, comprising of two training sessions up to one week apart, after the third cycle of chemotherapy. Each session will start with a 10- minute aerobic warm-up using a cross-trainer (Glidex, Technogym®, Gamettola, Italy). During the first familiarization session participants will be introduced to four upper-body exercises (chest press, latissimus pull down, triceps extension (Technogym®, Gamettola, Italy) and biceps curl (free weights)) followed by a 1RM strength test in each exercise. At the second familiarization session, two sets of 10–15 RM will be performed and a new 1RM strength test will be undertaken to ensure accuracy of subsequent exercise prescription. Participants will engage in the first experimental session after the first cycle of docetaxel (fourth chemotherapy), followed by a wash-out period of 6 days. Two sets of 15–20 RM of each exercise will be performed during low-load resistance exercise and three sets of 5–8 RM during heavy-load. All sets will be performed to muscle fatigue in sessions individually supervised by the first author (a physical therapist with experience in exercise prescription for women with breast cancer) at training facilities located at Rigshospitalet.

**Outcomes (pre- and post, 24- and 72-hours after resistance exercise)**

Measurements will be performed by medical technicians with no knowledge of group (low- / high-load first) allocation at the Department of Clinical Physiology and...
Nuclear Medicine at the Copenhagen University Hospital, Rigshospitalet. Participants are advised to maintain their normal activities during study participation. At all assessment points, participants will be asked about their physical activities, and any extraordinary activities will be recorded.

**Primary outcome**

*Extracellular fluid* BIS (SFB7, Impedimed, Brisbane, Australia) directly measures the impedance of extracellular fluid and has a high reliability for detecting BCRL [14, 16, 17] (intra-class correlation coefficient (ICC) = 0.99) [18]. Participants will be positioned in supine with arms and legs slightly abducted from the trunk with palms facing down. Utilizing the principle of equipotentials, four single tab electrodes will be placed in a tetrapolar arrangement [17]. Measurement electrodes will be placed on the dorsal of the wrist midway between the styloid processes, with current drive electrodes placed five centimeters distally on the dorsal side over the third metacarpal of the hand, and approximately midway on the third metatarsal on the dorsum of the foot [17, 19]. Each limb will be measured at a range of frequencies using the manufacturer’s software. The ratio of impedance between the at-risk and non-affected limb will be calculated and converted into a L-Dex score.

**Secondary outcomes**

*Arm volume* Dual energy x-ray absorptiometry (DXA) (Lunar Prodigy Advanced Scanner, GE Healthcare, Madison, WI) measures tissue composition using a three-compartment model that is sensitive to changes in upper-limb tissue composition [20, 21]. Using previously derived densities for: fat (0.9 g/ml); lean mass (1.1 g/ml); bone mineral content (BMC) (1.85 g/ml), the measured DXA tissue weights will be transformed into estimated arm volumes [20, 21].

Participants will be positioned on the scan-table, lying supine with the arm separated from the trunk. If necessary a Velcro band will be used over the breast to ensure space between the arm and truncus. Each arm will be scanned separately. Small animal software (Encore version 14.10) will be used to analyze the scans as described by Gjorup et al. [20]. Scans will be point typed where soft tissue is marked as bone, whereby regions of interest (ROIs) will be drawn around the hand and the arm on every scan (Fig. 2). All scans will be analyzed by one examiner (last author) with experience in analyzing DXA scans.

*Subjective assessment of symptoms* The severity of symptoms related to arm lymphedema including swelling, heaviness, pain and tightness, will be monitored using a visual analogue scale, whereby 0 represents no discomfort and 10 is indicative of very severe discomfort [10].

Fig. 2 DXA regions of interest
One year follow-up
Statistically, it is assumed that some of the participants in the study will develop arm lymphedema. Furthermore, previous studies have found a highly variable response to resistance exercise [10, 22]. A one year exploratory, hypothesis generating follow-up has been planned as it provides an opportunity to determine how many participants develop arm lymphedema and whether individual variability in response to the resistance exercise sessions is related to subsequent lymphedema incidence. Measurements will include 1RM strength in the four resistance exercises, DXA, BIS and symptom severity (VAS) as described, and a structured interview by the first author to determine other known and theoretical risk factors.

Blinding
All data collection and analysis will be conducted by study personnel with no knowledge of group (low-/ high-load first) allocation.

Sample size and analytical plan
The sample size calculation is based on changes in L-Dex scores between baseline and 72 h post-resistance exercise sessions. From results of Cormie et al. [10] we hypothesize the standard deviation in the distribution to be 1.9 units. No published normative change scores exist for the at-risk population, as well as no evidence regarding a threshold for a clinically significant acute change. For patients with BCRL a change score of 2L-Dex units is considered clinically relevant based on clinical experience. We believe that an L-Dex of 2 units is too conservative in the at-risk population, and have therefore set a threshold at 3L-Dex units. Thus, if there is no difference between groups, then 18 patients are required to be 90 % sure that the limits of a two-sided 90 % confidence interval will exclude a difference in means of more than 3.0. To allow for possible drop-outs we plan to include 20 patients.

Data will be analyzed using the Statistical Package for Social Sciences (SPSS) software (version 19) for Windows (IBM SPSS, Chicago, IL). Analysis will include standard descriptive statistics and both intention to treat and per-protocol analysis will be performed. Using a generalized estimating equations framework for continuous outcomes to determine time (baseline, pre-, post, 24- and 72 h) and intervention (low-/ heavy-load) effects, the interaction between time and intervention will be considered [23]. Two-tailed $p < 0.05$ will be taken as evidence of statistical significance.

Safety and ethical considerations
The treating oncologist will have the overall responsibility for the participants. All personal data will be treated in accordance with existing rules and regulations.

A full body DXA scan utilizes weak x-rays and is not considered dangerous [24]. In this study, since only arms will be scanned the radiation dose is estimated to be 0.0001 mSv for both arms. Eight scans result in a total dose of 0.0008 mSv, which is less than the background radiation an average person is exposed to in one day in Denmark.

As about 20 % of women treated for breast cancer develop BCRL [1], it is expected that some of the participants in this study will develop BCRL. Participation in this study involves regular assessment of the at-risk arm during the study period, using some of the best technology to date. This allows for early detection of BCRL, which in turn would render a better prognosis, as early detection is associated with a better outcome [4]. If participants develop signs of swelling or an L-Dex score persisting over one week during the familiarization or experimental study period, they will be referred to the treating oncologist for lymphedema treatment and will be withdrawn from the study.

A completed SPIRIT checklist is included as Additional file 1.

Discussion
Participating in resistance exercise during adjuvant chemotherapy for breast cancer has been associated with increases in muscle strength [25–29], lean body mass [25, 28], and self-esteem [25], and has been found to mitigate fatigue and to maintain quality of life [29]. Furthermore, there is evidence to suggest that resistance exercise might be associated with a higher completion rate of planned chemotherapy [25]. Moreover, generalized edema characterized by an increase in the size of the interstitial compartment of extracellular fluid is a potential side effect to taxane-based chemotherapy [30, 31]. Thus, swelling as a consequence of increased fluid in addition to an impairment of lymph fluid transport, could potentially contribute to swelling of the at-risk arm. Hypothetically, this could be thwarted by resistance exercise due to increased lymph clearance likely through the effects of the muscle pump [32, 33], lending additional rationale for instigating resistance exercise during adjuvant chemotherapy.

To our knowledge, studies investigating the safety and efficacy of resistance exercise in patients at risk for BCRL have utilized low- to moderate-resistance exercise intensities [6, 7], with only one cross-sectional study [11] investigating heavy-load resistance exercise. Indeed, in a paper identifying the top 10 research questions related to physical activity and cancer survivorship, Courneya et al. [34] highlighted the need for studies investigating safety and optimal exercise prescription, and specifically the role of vigorous-intensity activity, as important research areas [34]. The rational for utilizing heavy-load resistance exercise is supported by exercise science literature that indicates
that this higher training intensity can lead to additional
benefits as a dose–response relationship exists between
the load of resistance exercise and gains in muscular
structure and function [35, 36]. Furthermore, breast can-
cer survivors may suffer from losses of bone mass (par-
AAbbreviations
icularity those on aromatase inhibitors), at least in part
as a result of the catabolic effects of treatment. Resis-
tance exercise interventions with lower loads have not
yielded significant training effects on bone mineral den-
sity [27, 37]. It has been postulated that the absence of a
measurable effect on bone mass density is related to the
Adaptive nature of bone that requires heavier loads [37],
as heavy-load resistance exercise has been identified as
an osteogenic exercise modality in women without can-
cer [38]. Thus, establishing the safety of heavy-load re-
sistance exercise is prudent and of significance for the
breast cancer population.

No standardized measurement method exists to diag-
ose or monitor BCRL [1, 20, 21], with a variety of tech-
niques and definitions used. Early BCRL is characterized
by an increase in extracellular fluid. Indirect measure-
sment methods such as circumference, water displace-
ment, and perometry measure volume of the entire limb
to detect small changes in extracellular fluid which ac-
counts for approximately 25 % of the total limb, and do
not differentiate between tissue types [5, 18]. In contrast,
BIS directly measures lymph fluid change by measuring
the impedance to a low level electrical current allowing
for a sensitive [21, 39] and reliable measurement method
to detect extracellular fluid changes among at-risk breast
cancer survivors [39]. Furthermore, BIS is fast and easy
to administer, and as impedance measures are reported
as an L-Dex value, inherent volume differences associated
with hand dominance are taken into account [5, 39]. How-
ever, BIS loses its sensitivity to monitor BCRL over time
as lymphedema progresses into later stages, whereby the
excess extracellular fluid initially characterizing BCRL is
replaced with adipose tissue [5, 21].

DXA is another measurement method that can differen-
tiate between tissue types giving an estimate of BMC, fat
mass and lean mass where the lean mass component in-
cludes extracellular fluid [20, 21, 40]. DXA has been found
to be sensitive to changes in tissue composition, making it
an ideal measurement method to monitor BCRL over time
as fluid components are replaced with adipose tissue. Fur-
thermore, DXA allows for analysis of separate regions of
the arm, of potential clinical importance for patients
where swelling is confined to a specific region of the arm
or hand [20, 21, 40, 41]. In this study we scan the arms
separately and use software with a high resolution allow-
ing for more precise definition of ROIs and the possibility
to define bone and soft tissue manually as described by
Gjorup et al., with a low inter-rater variation (ICC ≥.9990)
[20]. To the authors’ knowledge, this is the first time that

This exploratory study utilizes a cross-over design to de-
termine acute changes in extracellular fluid and arm vol-
ume. This design lends more statistical power, with the
practical advantage of a smaller sample size, as between-
patient variation is inherently eliminated [42], providing a
framework for an efficient comparison between the two
resistance exercise loads. However, this study can only
provide us with information regarding extracellular fluid
and arm volume changes after one resistance exercise ses-
sion, limiting the generalizability to repeated resistance ex-
ercise training and long-term effects on arm volume. Nonethe-
less, this study can lend initial evidence regarding the
safety of heavy-load lifting and can help guide future
studies and optimal exercise prescription.

Finally, women at risk for BCRL still receive risk reduc-
tion advice including avoiding heavy lifting [43, 44]. This
advice can lead to women being apprehensive about lifting
heavy loads with consequences for daily living (e.g., not
lifting children, groceries, etc.). However, this advice is not
based on research and knowledge gained from this study
can provide a preliminary evidence base for guiding risk
reduction practices involving intermittent heavy-load ac-
tivity necessary for daily living.

Additional file

**Additional file 1:** SPIRIT checklist. (DOC 121 kb)

**Abbreviations**

AND, axillary lymph node dissection; BCRL, breast cancer-related arm
lymphedema; BIS, bioimpedance spectroscopy; CTC, common toxicity
criteria; DXA, dual-energy x-ray absorptiometry; ICC, intraclass correlation
coefficient; L-Dex, lymphedema index; ROI, region of interest

**Acknowledgments**

We would like to thank exercise physiologist Christian Lillelund for his
contribution to the conception of the study.

**Funding**

This study is internally funded by the University Hospitals Centre for Health
Research (UCSF), Copenhagen University Hospital, Rigshospitalet. UCSF is also
the trial sponsor and play a role in the conception, execution, analysis and
interpretation of data.

**Availability of data and material**

A data management plan has been approved by the regional Danish Data
Protection Agency (30-1430). No data monitoring committee has been
formed for the study.
The datasets supporting the conclusions of the study are stored in a secure
database at the Copenhagen University Hospital, Rigshospitalet and will
become available as additional files upon publication of a results article.

**Authors’ contributions**

KB: Conception and design, drafting of manuscript and final approval for
publication. SH: Conception and design, drafting of manuscript and final
approval for publication. LA: Conception and design, drafting of manuscript
and final approval for publication. TM: Conception and design, drafting of
manuscript and final approval for publication. KB: Design and final approval
for publication. BE: Design and final approval for publication. PO: Conception and design, drafting of manuscript and final approval for publication.

Authors’ information
KB: PhD-student, MHS, PT
SH: Professor, Principal research fellow, PhD
LA: Professor, PhD, RN, Sociologist
TM: Associate Professor, PhD, MPH, RN
KBC: Associate Professor, Statistician
BE: Professor, Chief Physician
PO: Chief Physician

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable

Ethics approval and consent to participate
This study has been approved by the Danish Capital Regional Ethics Committee (H-3-2014-147). All participants will provide written informed consent. If protocol modifications are necessary, amendments to the trial registries will be made after approval from the ethics committees.

Dissemination
Results from the trial will be disseminated through publication and presentation at relevant conferences and seminars regardless of the magnitude or direction of effect.

Author details
1University Hospitals Centre for Health Research (UCSF), Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark. 2Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove Urban Village, Kelvin Grove, Queensland 4059, Australia. 3Department of Public Health; Section of Biostatistics, University of Copenhagen, Øster Farimagsgade 5, 1014 Copenhagen K, Denmark. 4DBC, Afsnit 2501, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark. 5Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Received: 28 December 2015 Accepted: 11 July 2016
Published online: 22 July 2016

References
1. DiSpiro T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15.
2. Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Salin L. Lymphoedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27(3):390–7.
3. Morgan PA, Franks PJ, Moffatt CJ. Health-related quality of life with lymphoedema: a review of the literature. Int Wound J. 2005;2(1):47–62.
4. Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;118(8 Suppl):2237–49.
5. Hayes SC, Speck RM, Reitemeier S, Schmitz KH. Does the effect of weight lifting on lymphoedema following breast cancer differ by diagnostic method: results from a randomized controlled trial. Breast Cancer Res Treat. 2011;130(1):227–34.
6. Cheerna BS, Kilbreath SL, Fahey PP, Delaney GP, Atlantis E. Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;148(2):249–68.
7. Paramanandam VS, Roberts D. Weight training is not harmful for women with breast cancer-related lymphoedema: a systematic review. J Physiother. 2014;60(3):136–43.
8. Baechle TR, ERW, Watthen D. Essentials of strength training and conditioning. In: Baechle TR, editor. Human kinetics. 2nd ed. Champaign: ERW; 2000.
9. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. Med Sci Sports Exerc. 2009;41(3):687–708.
10. Cormie P, Galvao DA, Spyr N, Newton RJ. Neither heavy nor light load resistance exercise acutely exacerbates lymphedema in breast cancer survivors. Int J Cancer Ther. 2013;12(5):423–32.
11. Bloomquist K, Karlsmark T, Christensen KB, Adamsen L. Heavy resistance training and lymphoedema: prevalence of breast cancer-related lymphoedema in participants of an exercise intervention utilizing heavy load resistance training. Acta Oncol. 2014;53(2):216–25.
12. Adamsen L, Quist M, Andersen C, Møller T, Herstedt J, Lonborg D, Bødsøgaard MT, Vistisen K, Møldgaard J, Christiansen B, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009;339: b3410.
13. Cheville AL, McGarvey CL, Petrek JA, Russo SA, Thadens SR, Taylor ME. The grading of lymphoedema in oncology clinical trials. Semin Radiat Oncol. 2003;13(3):214–25.
14. Ward LC, Dylke E, Czerniec S, Isenring E, Kilbreath SL. Confirmation of the reference impedance ratios used for assessment of breast cancer-related lymphoedema by bioelectrical impedance spectroscopy. Lymphat Res Biol. 2011;9(1):47–51.
15. Hayes SC, Rye S, Disipio T, Yates P, Bashford J, Pyke C, Saunders C, Battistutta D, Eakin E. Exercise for health: a randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. Breast Cancer Res Treat. 2013;137(1):175–86.
16. Ward LC, Bunce IH, Cornish BH, Mirolo BR, Thomas BJ, Jones LC. Multi-frequency bioelectrical impedance augments the diagnosis and management of lymphoedema in post-mastectomy patients. Eur J Clin Invest. 1992;22(11):751–4.
17. Cornish BH, Jacobs A, Thomas BJ, Ward LC. Optimizing electrode sites for segmental bioimpedance measurements. Physiol Meas. 1999;20(3):241–50.
18. Cornish BH, Thomas BJ, Ward LC, Hinch C, Bunce IH. A new technique for the quantification of peripheral edema with application in both unilateral and bilateral cases. Angiology. 2002;53(1):41–7.
19. Kilbreath SL, Lee MJ, Refshauge KM, Keith JM, Ward LC, Simpson JM, Black D. Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer. 2013;21(8):2207–15.
20. Gjorup C, Zerah B, Hendel HH. Assessment of volume measurement of breast cancer-related lymphedema by three methods: circumference measurement, water displacement, and dual energy X-ray absorptiometry. Lymphat Res Biol. 2010;8(2):111–9.
21. Newman AL, Rosenhall L, Towers A, Hodgson P, Shay CA, Tidhar D, Viganò A, Kilgour RD. Determining the precision of dual energy x-ray absorptiometry and bioelectrical impedance spectroscopy in the assessment of breast cancer-related lymphedema. Lymphat Res Biol. 2013;11(2):104–9.
22. Lane KN, Dolan LB, Worsley D, McKenzie DC. Upper extremity lymphatic function at rest and during exercise in breast cancer survivors with and without lymphedema compared with healthy controls. J Appl Physiol (1985). 2007;103(3):917–25.
23. Cormie P, Singh B, Hayes S, Peake JM, Galvao DA, Taaffe DR, Spyr N, Nosaka K, Cornish B, Schmitz KH et al. Acute inflammatory response to low-, moderate-, and high-load resistance exercise in women with breast cancer-related lymphedema. Int J Cancer Ther. 2015;e-pub ahead of print.
24. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs Jr RW, Lentle BC. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8(4):371–8.
25. Counsey KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallerance JK, Lane K, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25(28):4396–404.
26. Counsey KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Cook D, Jespersen D, Proulx C, et al. Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst. 2013;105(23):1821–2.
27. Schwartz AL, Winters-Stone K, Gallucci B. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum. 2007;34(3):627–33.

28. Battaglini C, Bottaro M, Demnethy C, Rae L, Shields E, Kirk D, Hackney AC. The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment. Sao Paulo Med J. 2007;125(1):22–8.

29. Schmidt ME, Wiskemann J, Armbrust R, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. Int J Cancer. 2015;137(2):471–80.

30. Bronstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004;287(2):H963–8.

31. Qin YY, Li H, Guo XJ, Ye XF, Wei X, Zhou YH, Zhang XL, Wang C, Qian W, Lu J, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One. 2011;6(1):e16946.

32. Lane K, Worsley D, McKenzie D. Exercise and the lymphatic system: implications for breast-cancer survivors. Sports Med. 2005;35(6):461–71.

33. Goddard AA, Pierce CS, McLeod KJ. Reversal of lower limb edema by calf muscle pump stimulation. J Cardiopulm Rehabil Prev. 2008;28(3):174–9.

34. Courneya KS, Rogers LQ, Campbell KL, Vallance JK, Friedenreich CM. Top 10 research questions related to physical activity and cancer survivorship. Res Q Exerc Sport. 2015;86(6):107–16.

35. Fry AC. The role of resistance exercise intensity on muscle fibre adaptations. Sports Med. 2004;34(10):663–79.

36. Cormie P, Pumpa K, Galvao DA, Turner E, Spy N, Saunders C, Zissiadis Y, Newton RU. Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial. J Cancer Surviv. 2013;7(3):413–24.

37. Winters-Stone KM, Laudermilk M, Woo K, Brown JC, Schmitz KH. Influence of weight training on skeletal health of breast cancer survivors with or at risk for breast-cancer-related lymphedema. J Cancer Surviv. 2014;8(2):260–8.

38. Kohrt WM, Bloomfield SA, Little KD, Nelson ME, Yingling VR. American College of Sports Medicine Position Stand: physical activity and bone health. Med Sci Sports Exerc. 2004;36(11):1985–96.

39. Fu MR, Cieland CM, Guth AA, Kayal M, Haber J, Cartwright F, Kleinman R, Kang Y, Sacigliola J, Axelson D. L-dex ratio in detecting breast cancer-related lymphedema: reliability, sensitivity, and specificity. Lymphology. 2013;46(2):85–96.

40. Bronson H, Ohlin K, Olsson G, Karlsson MK. Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol. 2009;7(1):3–10.

41. Czerniec SA, Ward LC, Meekin JD, Kibbeath SL. Assessment of segmental arm soft tissue composition in breast cancer-related lymphedema: a pilot study using dual energy X-ray absorptiometry and bioimpedance spectroscopy. Lymphat Res Biol. 2015;13(1):33–9.

42. Altman DG. Practical statistics for medical research. London: Chapman & Hall/CRC; 1991.

43. Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, Rowden D. Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer. 2012;118(8 Suppl):2207–16.

44. Lee TS, Kibbeath SL, Sullivan G, Refshauge KM, Beith JM. Patient perceptions of arm care and exercise advice after breast cancer surgery. Oncol Nurs Forum. 2010;37(1):85–91.